Dr. Reddy's Laboratories Limited (DRREDDY) Operating Income 2022–2026

Name: Dr. Reddy's Laboratories Limited (DRREDDY) operating income history 2022-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Dr. Reddy's Laboratories Limited annual operating income for fiscal 2026 was ₹50.1 billion, a decrease of 30.4% from ₹72.0 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

DRREDDY Annual Operating Income

Operating Income (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Operating Income (EBIT)	₹50.1B	₹72.0B	₹65.3B	₹59.1B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DRREDDY Quarterly Operating Income

Operating Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Operating Income (EBIT)	₹3.0B	₹829M	₹14.3B	₹17.9B	₹16.8B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Operating Income at Comparable Companies

ZYDUSLIFE Operating Income — Zydus Lifesciences Limited
CIPLA Operating Income — Cipla Limited
LAURUSLABS Operating Income — Laurus Labs Limited
AUROPHARMA Operating Income — Aurobindo Pharma Limited
LUPIN Operating Income — Lupin Limited
MANKIND Operating Income — Mankind Pharma Limited

More DRREDDY metrics: Revenue · Gross Profit · Net Income · EPS · Free Cash Flow

All DRREDDY financial statements → Interactive DRREDDY charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.